Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1Classical hematology 1

Conditions

Hematologic Neoplasms 2Graft vs Host Disease 2Myelodysplastic Syndromes 1Lymphoma, Mantle-Cell 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Hodgkin Disease 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Rituximab 30ibrutinib 26Bendamustine Hydrochloride 18Cyclophosphamide 17acalabrutinib 14fludarabine 13Lenalidomide 11zanubrutinib 10venetoclax 9Vincristine 7Bortezomib 7pirtobrutinib 5brexucabtagene autoleucel 5Prednisone 5Doxorubicin 5temsirolimus 4parsaclisib 4aflibercept 4Gemcitabine 4ublituximab 3orelabrutinib 3loncastuximab tesirine 3idelalisib 3ibritumomab tiuxetan 3Sensitivity and Specificity 3Antigens, CD19 3tositumomab I-131 2tazemetostat 2pembrolizumab 2fludarabine phosphate 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Lymphoma, Mantle-Cell × Calcineurin Inhibitors × Clear all
NCT03320642 2025-10-21

GRAVITAS-119: Itacitinib in Combination With Calcineurin Inhibitor-Based Interventions for the Prophylaxis of Graft-Versus Host Disease

Incyte Corporation

Phase 1 Terminated
84 enrolled
Classical hematologyLymphoidMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Graft vs Host Disease, Hodgkin Disease, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Hematologic Neoplasms, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡